Cerenome, through its subsidiary CNSide Diagnostics, has signed a national in-network agreement with Aetna to provide reimbursement for CNSide's cerebrospinal fluid tumor cell enumeration and molecular profiling tests. This agreement adds about 26 million Aetna members, expanding CNSide's payer coverage to approximately 190 million lives across the US. The tests support diagnosis and treatment decisions for central nervous system cancers, with clinical validation from multiple studies. This milestone advances Cerenome's strategy to secure broad reimbursement and improve patient access to critical CNS cancer diagnostics.
Cerenome's CNSide news provides context for health sector investors. As of Nov 04, 2026 18:41 WIB, 118 of 150 priced US health stocks on Pluang rose, 24 fell. Notable movers include NUWE at USD 5.38 with a 8.97% drop and 100% sell order activity, OSCR at USD 34.95 up 7.84% with 84% buy orders, and RVTY at USD 173.82 up 6.32% with 100% buy orders.
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
Dimensional Fund Advisors Ltd. has disclosed an interest in 1,516,595 ordinary shares of DCC Energy plc, representing 1.78% of the company's shares as of November 3, 2026. The disclosure follows regulatory requirements under the Irish Takeover Panel ...
Transocean's Q3 results missed revenue and EPS expectations, causing a 5.3% share drop. However, the company remains a buy due to a growing backlog of $12.7 billion combined with Valaris and reduced net debt of $4.23 billion. The Valaris merger is ex...
